|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of GSTO1 A140D and GSTO2 N142D Gene Variations with Breast Cancer Risk
|
28670895 |
2017 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of GSTO1 A140D and GSTO2 N142D Gene Variations with Breast Cancer Risk
|
28670895 |
2017 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our findings supported a role of the GSTO1 rs4925 SNP in the risk of sporadic AD in southern Italy, suggesting that this and other variants of the GSTO1 gene could be implicated in AD pathogenesis.
|
20818931 |
2010 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Two missense polymorphisms in exon 4 of GSTO1 (Ala140Asp and Glu155DeltaGlu) were detected and tested for their association with AD, VaD, and stroke.
|
15623683 |
2004 |
|
Neurodegenerative Disorders
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two coding single nucleotide polymorphisms (SNPs) supposedly affect their functions: GSTO1*C419A (rs4925) causing alanine to aspartate substitution (*A140D) and GSTO2*A424G (rs156697) causing asparagine to aspartate substitution (*N142D), and have been associated with several neurodegenerative diseases and cancers.
|
30224590 |
2018 |
|
Skin lesion
|
|
0.010 |
GeneticVariation
|
BEFREE |
In addition, the haplotype CT between rs4925 and rs11191979 appeared to confer a high risk of arsenic-included skin lesions (OR = 1.377, 95% CI = 1.03-1.84), as did the haplotype GCG among rs156697, rs157077 and rs2297235 (OR = 2.197, 95% CI = 1.08-4.44).
|
29323258 |
2018 |
|
Skin Manifestations
|
|
0.010 |
GeneticVariation
|
BEFREE |
The present study demonstrates significant correlation between severities of skin manifestations with their whole genome DNA methylation status as well as with a particular polymorphism (Ala 140 Asp) status in arsenic metabolizing enzyme Glutathione S-transferase Omega-1 (GSTO1) in arsenic-exposed population of the district of Nadia, West Bengal, India.
|
28436716 |
2017 |
|
Spinocerebellar Ataxia Type 2
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective is to assess the association of GSTO1 rs4925 and GSTO2 rs2297235 SNPs on the clinical phenotype in SCA2 patients.
|
28017238 |
2017 |
|
Impaired cognition
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hence, besides proposing rs4925 as a genetic marker for cognitive impairment, this work also emphasized the importance of carefully characterized controls in addition to well-diagnosed patients in case-control studies.
|
27259244 |
2016 |
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
To clarify the role of genetic polymorphisms of GSTO1 (rs4925) and GSTO2 (rs156697) in individual susceptibility to urinary bladder cancer.
|
25716313 |
2015 |
|
Precursor B-cell lymphoblastic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study found no significant association between Pre-B ALL and GSTO1 A140D and GSTO2 N142D polymorphisms.
|
25726706 |
2015 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study found no significant association between Pre-B ALL and GSTO1 A140D and GSTO2 N142D polymorphisms.
|
25726706 |
2015 |
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
To clarify the role of genetic polymorphisms of GSTO1 (rs4925) and GSTO2 (rs156697) in individual susceptibility to urinary bladder cancer.
|
25716313 |
2015 |
|
TARSAL-CARPAL COALITION SYNDROME
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that carriers of mutant GSTO2*G/G genotype were at increased risk of the development of TCC (OR 2.6, 95% CI 1.2-5.8, p = 0.041), while GSTO1 rs4925 polymorphism was not significantly associated with TCC risk (p = 0.450).
|
25716313 |
2015 |
|
Hematuria
|
|
0.010 |
GeneticVariation
|
BEFREE |
In addition, patients with the GSTP1 rs1695 AA genotype had an increased risk of irritative voiding symptoms; while patients with the GSTO1 rs4925 CC genotype had a decreased risk of hematuria.
|
26354850 |
2015 |
|
Age-related cataract
|
|
0.010 |
GeneticVariation
|
BEFREE |
rs4925 (Ala140Asp) of glutathione S-transferase omega-1 and rs156697 (Asn142Asp) of glutathione S-transferase omega-2 polymorphisms in 100 patients with age-related cataract and 130 controls were assessed.
|
23927022 |
2014 |
|
Lung diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
The polymorphism A140D of GSTO1-1 has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and lung disease in non-exposed populations, suggesting that GSTO1-1 involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.
|
22293942 |
2012 |
|
Metabolic Syndrome X
|
|
0.010 |
GeneticVariation
|
BEFREE |
The increased risk associated with low primary methylation rate was further modified by the GSTO1 A140D polymorphism, with the D allele carriers showing a slightly higher risk for MetS.
|
22440634 |
2012 |
|
Childhood Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The polymorphism A140D of GSTO1-1 has been not only associated with distinct urinary profile of arsenic metabolites in populations chronically exposed to iAs in drinking water, but also with higher risk of childhood leukemia and lung disease in non-exposed populations, suggesting that GSTO1-1 involvement in other physiologic processes different from toxics metabolism could be more relevant than is thought.
|
22293942 |
2012 |
|
Carotid Atherosclerosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Non-significant association between genetic polymorphisms of PNP Gly51Ser, Pro57Pro, As3MT Met287Thr, GSTO1 Ala140Asp, and GSTO2 A-183G and the risk for development of carotid atherosclerosis were observed.
|
21605854 |
2011 |
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Diplotype analysis showed that among subjects exposed to high levels of arsenic, the AGG/AGG variant of GSTO1 Ala140Asp, GSTO2 5'UTR (-183)A/G, and GSTO2 Asn142Asp was associated with an increased cancer risk (HRs, 4.91, 95% CI, 1.02-23.74) when compared to the all-wildtype reference, respectively.
|
21798077 |
2011 |
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Diplotype analysis showed that among subjects exposed to high levels of arsenic, the AGG/AGG variant of GSTO1 Ala140Asp, GSTO2 5'UTR (-183)A/G, and GSTO2 Asn142Asp was associated with an increased cancer risk (HRs, 4.91, 95% CI, 1.02-23.74) when compared to the all-wildtype reference, respectively.
|
21798077 |
2011 |
|
Malignant neoplasm of ovary
|
|
0.010 |
GeneticVariation
|
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |